Neurocircuitry underlying the preferential sensitivity of prefrontal catecholamines to low-dose psychostimulants

Neuropsychopharmacology

Volumn 38, Issue 6, 2013, Pages 1078-1084

  Schmeichel, Brooke E ^a   Berridge, Craig W ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

ADHD; dopamine; norepinephrine; psychostimulants; reuptake; ritalin

Indexed keywords

CATECHOLAMINE; DOPAMINE; METHYLPHENIDATE; NORADRENALIN;

ARTICLE; ATTENTION DEFICIT DISORDER; LOW DRUG DOSE; MALE; MICRODIALYSIS; NEUROCIRCUITRY; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SENSITIVITY ANALYSIS; SEPTUM PELLUCIDUM;

ANIMALS; CATECHOLAMINES; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICRODIALYSIS; NERVE NET; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84878599669     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.6     Document Type: Article

References (47)

1. Arnsten AF (2009). Toward a new understanding of attentiondeficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 23(Suppl 1): 33-41.
2. Arnsten AFT, Castellanos FX (2002). Neurobiology of attention regulation and its disorders. In: Martin AScahill LCharney DLeckman J (eds) Textbook of Child and Adolescent Psychopharmacology. Oxford University Press: New York, pp 99-109.
3. Berridge CW (2006). Neural substrates of psychostimulantinduced arousal. Neuropsychopharmacology 31: 2332-2340.
4. Berridge CW, Devilbiss DM (2011). Psychostimulants as cognitive enhancers: the prefrontal cortex, catecholamines, and attentiondeficit/ hyperactivity disorder. Biol Psychiatry 69: e101-e111.
5. Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B et al (2006). Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 60: 1111-1120.
6. Berridge CW, Foote SL (1996). Enhancement of behavioral and electroencephalographic indices of waking following stimulation of noradrenergic beta-receptors within the medial septal region of the basal forebrain. J Neurosci 16: 6999-7009.
7. Berridge CW, Stalnaker TA (2002). Relationship between low-dose amphetamine-induced arousal and extracellular norepinephrine and dopamine levels within prefrontal cortex. Synapse 46: 140-149.
8. Biederman J (2003). Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. J Clin Psychiatry 64(Suppl 11): 3-8.
9. Bonanno G, Fontana G, Fedele E, Robino G, Raiteri M (1989). Presynaptic mechanisms underlying the gamma-aminobutyric acid-evoked receptor-independent release of [3H]norepinephrine in rat hippocampus. J Neurochem 52: 1854-1858.
10. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH et al (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27: 699-711.
11. Carboni E, Silvagni A, Vacca C, Di CG (2006). Cumulative effect of norepinephrine and dopamine carrier blockade on extracellular dopamine increase in the nucleus accumbens shell, bed nucleus of stria terminalis and prefrontal cortex. J Neurochem 96: 473-481.
12. Carboni E, Tanda GL, Frau R, Di CG (1990). Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55: 1067-1070.
13. Cardinal RN, Pennicott DR, Sugathapala CL, Robbins TW, Everitt BJ (2001). Impulsive choice induced in rats by lesions of the nucleus accumbens core. Science 292: 2499-2501.
14. Castellanos FX, Tannock R (2002). Neuroscience of attentiondeficit/ hyperactivity disorder: The search for endophenotypes. Nat Rev Neurosci 3: 617-628.
15. Chamberlain SR, Del CN, Dowson J, Muller U, Clark L, Robbins TW et al (2007). Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry 62: 977-984.
16. Christakou A, Robbins TW, Everitt BJ (2001). Functional disconnection of a prefrontal cortical-dorsal striatal system disrupts choice reaction time performance: implications for attentional function. Behav Neurosci 115: 812-825.
17. Clatworthy PL, Lewis SJ, Brichard L, Hong YT, Izquierdo D, Clark L et al (2009). Dopamine release in dissociable striatal subregions predicts the different effects of oral methylphenidate on reversal learning and spatial working memory. J Neurosci 29: 4690-4696.
18. Diamond A (2005). Attention-deficit disorder (attention-deficit/ hyperactivity disorder without hyperactivity): a neurobiologically and behaviorally distinct disorder from attention-deficit/ hyperactivity disorder (with hyperactivity). Dev Psychopathol 17: 807-825.
19. Dodds CM, Muller U, Clark L, van LA, Cools R, Robbins TW (2008). Methylphenidate has differential effects on blood oxygenation level-dependent signal related to cognitive subprocesses of reversal learning. J Neurosci 28: 5976-5982.
20. Drouin C, Wang D, Waterhouse BD (2007). Neurophysiological actions of methylphenidate in the primary somatosensory cortex. Synapse 61: 985-990.
21. Floresco SB, Braaksma DN, Phillips AG (1999). Thalamic-corticalstriatal circuitry subserves working memory during delayed responding on a radial arm maze. J Neurosci 19: 11061-11071.
22. Gabbott PL, Warner TA, Jays PR, Salway P, Busby SJ (2005). Prefrontal cortex in the rat: projections to subcortical autonomic, motor, and limbic centers. J Comp Neurol 492: 145-177.
23. Galli T, Godeheu G, Artaud F, Desce JM, Pittaluga A, Barbeito L et al (1991). Specific role of N-acetyl-aspartyl-glutamate in the in vivo regulation of dopamine release from dendrites and nerve terminals of nigrostriatal dopaminergic neurons in the cat. Neuroscience 42: 19-28.
24. Gamo NJ, Wang M, Arnsten AF (2010). Methylphenidate and atomoxetine enhance prefrontal function through alpha2-adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry 49: 1011-1023.
25. Giros B, Wang YM, Suter S, McLeskey SB, Pifl C, Caron MG (1994). Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopaminenorepinephrine transporters. J Biol Chem 269: 15985-15988.
26. Greenhill LL (2001). Clinical effects of stimulant medication in ADHD. In: Solanto MVArnsten AFTCastellanos FX (eds) Stimulant Drugs and ADHD: Basic and Clinical Neuroscience. Oxford University Press: New York, pp 31-71.
27. Gu H, Wall SC, Rudnick G (1994). Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem 269: 7124-7130.
28. Kelley AE, Gauthier AM, Lang CG (1989). Amphetamine microinjections into distinct striatal subregions cause dissociable effects on motor and ingestive behavior. Behav Brain Res 35: 27-39.
29. Kuczenski R, Melega WP, Cho AK, Segal DS (1997). Extracellular dopamine and amphetamine after systemic amphetamine administration: comparison to the behavioral response. J Pharmacol Exp Ther 282: 591-596.
30. Kuczenski R, Segal DS (2001). Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine. J Pharmacol Exp Ther 296: 876-883.
31. Kuczenski R, Segal DS (2002). Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci 22: 7264-7271.
32. Kuczenski R, Segal DS, Cho AK, Melega W (1995). Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 15: 1308-1317.
33. Mehta MA, Sahakian BJ, Robbins TW (2001). Comparative psychopharmacology of methylphenidate and related drugs in human volunteers, patients with ADHD, and experimental animals. In: Solanto MVArnsten AFTCastellanos FX (eds) Stimulant Drugs and ADHD: Basic and Clinical Neuroscience. Oxford University Press: New York, pp 303-331.
34. Moghaddam B, Berridge CW, Goldman-Rakic PS, Bunney BS, Roth RH (1993). In vivo assessment of basal and drug-induced dopamine release in cortical and subcortical regions of the anesthetized primate. Synapse 13: 215-222.
35. Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT (2002). Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 22: 389-395.
36. Raiteri M, Marchi M, Maura G, Bonanno G (1989). Presynaptic regulation of acetylcholine release in the CNS. Cell Biol Int Rep 13: 1109-1118.
37. Rapoport JL, Inoff-Germain G (2002). Responses to methylphenidate in attention-deficit/hyperactivity disorder and normal children: update 2002. J Atten Disord 6(Suppl 1): S57-S60.
38. Schmeichel B, Zemlan F, Berridge CW (2012). A selective dopamine reuptake inhibitor imporves prefrontal cortex-dependent cognitive function: potential relevance to attention deficit hyperactivity disorder. Neuropharmacology 64: 321-328.
39. Seidman LJ, Biederman J, Monuteaux MC, Valera E, Doyle AE, Faraone SV (2005). Impact of gender and age on executive functioning: do girls and boys with and without attention deficit hyperactivity disorder differ neuropsychologically in preteen and teenage years? Dev Neuropsychol 27: 79-105.
40. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI (1998). Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci 18: 2697-2708.
41. Solanto MV (2001). Attention-Deficit/Hyperactivity Disorder. In: Solanto MVArnsten AFTCastellanos FX (eds) Stimulant Drugs and ADHD: Basic and Clinical Neuroscience. Oxford University Press: New York, pp 3-30.
42. Spencer RC, Klein RM, Berridge CW (2012). Psychostimulants act within the prefrontal cortex to improve cognitive function. Biol Psychiatry 72: 221-227.
43. Spencer T, Biederman J, Wilens T (2004). Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 27: 373-383.
44. Turner DC, Blackwell AD, Dowson JH, McLean A, Sahakian BJ (2005). Neurocognitive effects of methylphenidate in adult attentiondeficit/ hyperactivity disorder. Psychopharmacology (Berl) 178: 286-295.
45. Valentini V, Frau R, Di CG (2004). Noradrenaline transporter blockers raise extracellular dopamine in medial prefrontal but not parietal and occipital cortex: differences with mianserin and clozapine. J Neurochem 88: 917-927.
46. Voorn P, Vanderschuren LJ, Groenewegen HJ, Robbins TW, Pennartz CM (2004). Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci 27: 468-474.
47. Yamamoto BK, Novotney S (1998). Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem 71: 274-280.